Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril valsartan plus dapagliflozin in acute heart failure with diuretic resistance
ChiCTR2600118845Phase 4Completed
- Sponsor
- Quzhou Kecheng District People's Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of sacubitril + valsartan and dapagliflozin in Acute Heart Failure (AHF) and Diuretic resistance (2 arms), sponsored by Quzhou Kecheng District People's Hospital. Primary endpoints: 24-hour urine output, Body weight and 1 more. Started Feb 2026; status: completed.
02
Drugs
sacubitril + valsartandapagliflozin
03
Conditions
Acute Heart Failure (AHF)Diuretic resistance
Beyond the preview
Go deeper on ChiCTR2600118845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118845.